Pre-earnings options volume in Taysha Gene Therapies is 3.3x normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 50.1%, or 0c, after results are released. Median move over the past eight quarters is 5.3%.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TSHA:
- TSHA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Taysha Gene Therapies presents preclinical in-vitro data on TSHA-102
- Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
- Taysha Gene Therapies announces second patient dosed with TSHA-102
- Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome